Rallybio Corporation is a biotechnology company focused on discovering and developing innovative therapies for rare and life-threatening diseases. The company specializes in creating breakthrough treatments that target the underlying causes of these conditions, aiming to significantly improve patient outcomes. Rallybio's research and development efforts are centered around advancing its robust pipeline of candidates designed to address critical unmet medical needs within the rare disease community. Through strategic partnerships and a commitment to scientific excellence, Rallybio is positioned to make a meaningful impact on patients' lives. Read More
Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Rallybio common stock to enable Rallybio to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Market. Pursuant to the Amendment, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on February 6, 2026. Rallybio expects that upon the opening of trading on February 6, 2026, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol “RLYB” and the new CUSIP number 75120L 209.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it received an equity milestone payment of $12.5 million from Recursion. The milestone payment was triggered by the initiation of additional preclinical studies for REV102, an investigational ENPP1 inhibitor in development for the treatment of hypophosphatasia (HPP).
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals for up to $25 million, including an upfront equity payment of $7.5 million and near term milestones. With the upfront payment, Rallybio expects its cash runway to extend into mid-2027.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments.
